BioSyent (CVE:RX) Share Price Passes Below Fifty Day Moving Average - Time to Sell?

Key Points

• BioSyent Inc. shares fell below their 50-day moving average of C$11.73, trading at C$11.70 during recent sessions.
• The company has a market capitalization of C$131.75 million and a relatively low debt-to-equity ratio of 2.90.
• BioSyent recently paid a quarterly dividend of $0.05 per share, resulting in an annualized yield of 1.7% with a payout ratio of 26.76%.

Shares of BioSyent Inc. (CVE:RX - ) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$11.73 and traded as low as C$11.70. BioSyent shares last traded at C$11.70, with a volume of 915 shares.

BioSyent Trading Down 0.4%

The firm has a market capitalization of C$131.75 million, a price-to-earnings ratio of 16.48 and a beta of 0.39. The company has a debt-to-equity ratio of 2.90, a quick ratio of 6.91 and a current ratio of 3.92. The business has a fifty day moving average price of C$11.73 and a 200 day moving average price of C$11.42.

BioSyent Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 15th. Stockholders of record on Friday, August 29th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 1.7%. BioSyent's payout ratio is 26.76%.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.